Compare LION & AAPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LION | AAPG |
|---|---|---|
| Founded | 1997 | 2009 |
| Country | Canada | China |
| Employees | N/A | 767 |
| Industry | Movies/Entertainment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.1B |
| IPO Year | 2025 | N/A |
| Metric | LION | AAPG |
|---|---|---|
| Price | $12.19 | $23.30 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 5 |
| Target Price | $11.14 | ★ $48.40 |
| AVG Volume (30 Days) | ★ 3.3M | 2.1K |
| Earning Date | 05-21-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,195,500,000.00 | N/A |
| Revenue This Year | N/A | $290.34 |
| Revenue Next Year | $22.79 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 7.00 | N/A |
| 52 Week Low | $5.65 | $20.11 |
| 52 Week High | $12.58 | $48.45 |
| Indicator | LION | AAPG |
|---|---|---|
| Relative Strength Index (RSI) | 66.62 | 43.11 |
| Support Level | $6.16 | $23.15 |
| Resistance Level | $12.58 | $25.23 |
| Average True Range (ATR) | 0.61 | 0.38 |
| MACD | 0.06 | -0.40 |
| Stochastic Oscillator | 84.82 | 18.97 |
Lionsgate Studios Corp is a motion picture and television studio operations aligned with the STARZ premium subscription platform to bring a varied portfolio of entertainment to consumers around the world. The group has two reportable business segments: the Motion Picture and Television Production reportable segments. Motion Picture consists of the development and production of feature films, the acquisition of North American and world-wide distribution rights. Television Production consists of the development, production, and world-wide distribution of television productions, including television series, television movies and mini-series, and non-fiction programming.
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies. The company's geographical segments include the United States and Mainland China.